中性粒细胞与淋巴细胞比值对TACE联合阿帕替尼治疗进展期肝癌疗效的预测价值  

The value of neutrophil-to-lymphocyte ratio in predicting the curative effect of TACE combined with apatinib for advanced hepatocellular carcinoma

作　　者：王富权 柴斌[1] 周国锋[1] WANG Fuquan;CHAI Bin;ZHOU Guofeng(Department of Rculioiog,Affiliated Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Hubei Provincial Key Laboratory of Molecular Imaging,Wuhan,Hubei Province 430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院放射科,分子影像湖北省重点实验室,武汉430022

出　　处：《介入放射学杂志》2021年第3期244-248,共5页Journal of Interventional Radiology

基　　金：中国健康促进基金会资助项目(XM-2018-011-0006-01)。

摘　　要：目的探究中性粒细胞与淋巴细胞比值(NLR)对TACE联合阿帕替尼治疗进展期肝癌疗效的预测价值。方法回顾性分析2015年4月至2018年4月接受TACE联合阿帕替尼治疗的87例进展期肝细胞癌患者的临床资料。根据患者治疗前NLR,将患者分成NLR≥2.95组和NLR<2.95组。通过比较两组患者的总生存时间(OS)、疾病进展时间(TTP)以及生存率来分析比较两组患者的疗效,并通过Cox回归模型分析影响患者OS的相关因素。结果NLR<2.95组患者的中位OS高于NLR≥2.95组患者(15个月比11个月,P<0.001),同时NLR<2.95组中位TTP较NLR≥2.95组长(7个月比4个月,P<0.001)。对比两组生存率,NLR<2.95组6、12及24个月生存率均高于NLR≥2.95组。通过多因素Cox回归分析,NLR≥2.95是影响患者OS的唯一独立危险因素(HR=2.67,95%CI:1.59~4.50,P<0.001)。结论进展期肝细胞癌患者接受TACE联合阿帕替尼治疗前NLR对疗效具有预测价值,治疗前NLR<2.95患者较NLR≥2.95患者预后好。Objective To explore the value of neutrophil-to-lymphocyte ratio(NLR)in predicting the curative effect of transhepatic arterial chemoembolization(TACE)combined with apatinib for advanced hepatocellular carcinoma(HCC).Methods The clinical data of 87 patients with advanced HCC,who received TACE combined with apatinib between April 2015 and April 2018,were retrospectively analyzed.According to the preoperative NLR,the patients were divided into NLR≥2.95 group and NLR<2.95 group.The overall survival time(OS),the time to disease progression(TTP)and the survival rate were compared between the two groups,and COX regression model was used to analyze the related factors affecting the patient’s OS.Results The median OS in NLR<2.95 group was 15 months,which was remarkably higher than 11 months in NLR≥2.95 group(P<0.001),while the median TTP in NLR<2.95 group was 7 months,which was significantly l onger than 4 months in NLR≥2.95 group(P<0.001).All the 6-,12-and 24-month survival ra tes in NLR<2.95 group were higher than those in NLR≥2.95 group.Multivariate COX regression analysis revealed that NLR≥2.95 was the only independent risk factor affecting OS(HR=2.67,95%CI:1.59-4.50,P<0.001).Conclusion NLR carries certain predictive value for the curative effect of TACE combined with apatinib in treating patients with advanced HCC.The patients having a preoperative NLR<2.95 are expected to obtain a better prognosis than the patients having a preoperative NLR≥2.95 can obtain.(J Intervent Radiol,2021,30:244-248).

关 键 词：阿帕替尼 经肝动脉化疗栓塞 中性粒细胞与淋巴细胞比值 预测因子 

分 类 号：R735.7[医药卫生—肿瘤]